7Baggers
 Published on: 2025-11-15 05:58:13  newser.com Sat, 15 Nov 2025 11:58:13 GMT
 Innate Pharma Secures Cash Flow Until End of September 2026  MarketScreener Thu, 13 Nov 2025 12:52:14 GMT
 Innate Pharma (IPHA) Reports Significant Revenue Decline in 9M 2  GuruFocus Thu, 13 Nov 2025 12:16:11 GMT
 Innate Pharma stock soars after FDA clears path for Phase 3 trial  Investing.com Canada Mon, 10 Nov 2025 17:29:16 GMT
 Pharma Boom: Innate Pharma Stock’s Rapid Ascent  StocksToTrade Mon, 10 Nov 2025 15:03:00 GMT
 Will Innate Pharma Surge on Upcoming Conference Call?  timothysykes.com Mon, 10 Nov 2025 14:18:00 GMT
 Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacut  GuruFocus Mon, 10 Nov 2025 11:53:17 GMT
 published on: 2025-11-05 22:26:46  newser.com Thu, 06 Nov 2025 04:26:46 GMT
 published on: 2025-11-05 05:29:49  newser.com Wed, 05 Nov 2025 11:29:49 GMT
 Innate Pharma Schedules Q3 2025 Results Conference Call  TipRanks Wed, 05 Nov 2025 11:27:46 GMT
 published on: 2025-11-05 00:05:56  newser.com Wed, 05 Nov 2025 06:05:56 GMT
 published on: 2025-11-04 23:56:01  newser.com Wed, 05 Nov 2025 05:56:01 GMT

Innate Pharma S.A
(NASDAQ:IPHA) 

IPHA stock logo

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tu...

Founded: 1999
IPO Price: $5.5 (Oct 17, 2019)
Full Time Employees: 247
CEO: Mondher Mahjoubi  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends